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Background: One of the most dreaded complications of septic shock is acute kidney injury. It occurs in around
50% of patients, with a mortality rate of about 60% at 3 months. There is no consensus on the optimal time to
initiate renal replacement therapy. Retrospective and observational studies suggest that early implementation of
renal replacement therapy could improve the prognosis for these patients.
Methods/design: This protocol summarizes the rationale and design of a randomized, controlled, multicenter trial
investigating the effect of early versus delayed renal replacement therapy in patients with severe acute kidney injury in
early septic shock. In total, 864 critically ill adults with septic shock and evidence of acute kidney injury, defined as the
failure stage of the RIFLE classification, will be enrolled. The primary outcome is mortality at 90 days. Secondary
outcomes include safety, number of days free of mechanical ventilation, number of days free of renal replacement
therapy, intensive care length of stay, in-hospital length of stay, quality of life as evaluated by the EQ-5D and renal
replacement therapy dependence at hospital discharge. The primary analysis will be intention to treat. Recruitment
started in March 2012 and will be completed by March 2015.
Discussion: This protocol for a randomized controlled study investigating the impact of the timing of renal
replacement therapy initiation should provide an answer to a key question for the management of patients with
acute kidney injury in the context of septic shock, for whom the mortality rate remains close to 60% despite
improved understanding of physiopathology and recent therapeutic advances.
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The incidence of acute kidney injury (AKI) in patients
with septic shock is around 50% [1-3]. In severe septic
shock, the need for renal replacement therapy (RRT)
contributes to increasing the risk of death from less than
40% in septic shock without AKI, to over 60% in the forms
associated with severe AKI requiring RRT [4]. It is now
proven that AKI associated with sepsis is an independent
risk factor for mortality [5,6], not just an epiphenomenon
related to the severity of the patients’ illness. The discrim-
ination of septic and non-septic AKI may have clinical
relevance for clinicians [7]. Some experimental studies
suggested that septic AKI may be characterized by a
distinct pathophysiology [8]. Thus, septic AKI may have
differences in clinical outcomes and responses to inter-
ventions compared to non-septic AKI.
Initiation of renal replacement therapy: state of the art
In chronic renal failure patients, there is no benefit to
initiating dialysis until the glomerular filtration rate
drops to less than 7 mL/min (except in case of uremic
syndrome). This is usually the beginning of dependence
on dialysis for these patients [9]. The situation is differ-
ent for patients with AKI, and the optimal time to start
RRT remains unknown. In current practice, the initi-
ation of RRT is sometimes very early (i.e. within the first
24 hr) [10], but may sometimes be delayed, whereby
diuresis is stimulated with diuretics, and RRT is started
only with the appearance of serious events, rather than
following a proactive decision based on the severity of
renal impairment [11]. Indeed, this attitude is justified by
the possibility that appropriate early treatment of sepsis
may limit the progression to renal failure [12].
In one historical study published in 1960, Teschan et al.
[13] introduced the concept of prophylactic hemodialysis,
advancing the hypothesis that the prevention of uremic
syndrome could prevent its complications, including sep-
sis. In this study, the threshold for defining RRT was a
urea level above 57 mmol/L, and dialysis was initiated 2 to
3 days after the diagnosis of AKI. Since this initial study,
several authors have compared early versus late therapy,
using different criteria and thresholds.
To the best of our knowledge, there is only one ran-
domized controlled trial to date that has examined the
benefits of early initiation of RRT in critically ill patients
with AKI [14]. In this study, which compared two doses
of dialysis, a secondary analysis compared early (within
12 hr of diagnosis) versus late hemofiltration (when the
patient fulfilled the conventional criteria for RRT, namely
a plasma urea level of >40 mmol/L, potassium of >6.5
mmol/L or severe pulmonary edema). On average, hemo-
filtration was started 7 hr after inclusion in the early group
and a mean of 42 hr after inclusion in the late group. No
significant differences were found, either in terms ofmortality at 28 days, or in terms of recovery of renal func-
tion. However, the study was undersized to answer the
question of the timing of RRT (analysis of 106 patients)
and was not specifically designed to test this hypothesis.
Several observational and retrospective studies that
have been conducted with patients with AKI, with or
without sepsis, suggest on the contrary that there may be a
benefit to early initiation of RRT [15-17]. A meta-analysis
published in 2008 by Seabra [18], which included studies
published over the last five decades, found a statistically
significant reduction in mortality with early RRT in 18
cohort studies, with a relative risk of 0.72 (95% confidence
interval 0.64 to 0.82, P < 0.001). In one prospective, multi-
center, observational study [19], the timing of RRT was
stratified into early and late by median urea (24.2 mmol/
L) and by median creatinine (309 μmol/L) at the time
RRT was started. There was no significant difference in
adjusted hospital mortality when stratified by median
serum urea at the time of RRT initiation. Conversely,
when stratified by creatinine levels, late RRT was associ-
ated with lower mortality. Timing was also categorized
temporally from ICU admission into early (<2 days),
delayed (2 to 5 days) and late (>5 days), and late RRT
was associated with increased mortality.
Other authors have tried to initiate very early RRT as
a treatment for the initial phase of septic shock, with
discordant results [20,21]. In these studies, hemofiltration
techniques were introduced before the onset of established
AKI, more with a view to immunomodulation than to
treating the AKI itself. Interestingly, a recent retrospective
multicenter observational study [22] found a U-shaped
association between the timing of RRT initiation and in-
hospital mortality, with reduced mortality when initiation
of RRT was between 2 and 3 days after ICU admission. The
peak mortality when RRT was initiated very early was
related to the extreme severity of disease in these patients,
whereas age and septic complications were responsible for
the highest mortality in the case of late RRT (after D4).
The overall results of these studies would seem to
indicate that there is a benefit from early initiation of RRT,
but the exact definition of early remains to be determined,
as does the definition of the criteria for AKI necessitating
RRT. The question of the right time to begin RRT remains
unanswered and controversial, and poses a real problem
in the management of patients with septic shock and AKI.
In this context, we propose a randomized, multicenter,
controlled trial on the impact on mortality of the timing
of RRT initiation in patients with acute kidney failure in
septic shock.
Objectives
The primary objective is to assess whether the timing of
RRT initiation (early versus delayed) has an impact on
mortality at 90 days in patients with AKI at the failure
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below in Study definitions), during the initial phase of
septic shock. The secondary objectives are: (1) to evalu-
ate the impact of early versus delayed initiation of RRT
on key secondary endpoints including: 28-day, 180-day
and 1-year mortality; number of days free of mechanical
ventilation; number of days free of RRT; ICU length of
stay; hospital length of stay; and 90-day and 1-year quality
of life as evaluated by the EQ-5D questionnaire; (2) to
compare the efficacy and safety of the two strategies in
terms of episodes of metabolic disorders, arrhythmia,
pulmonary edema, hypotension, hemorrhage and RRT
dependence at hospital discharge.
Methods/design
Study design, setting and patient population
This is a randomized, controlled, open-label, multicenter
study comparing two strategies for the management of
AKI occurring in patients in the initial phase of septic
shock: namely initiation of RRT within 12 hr of the
onset of AKI versus initiation of RRT after 48 to 60 hr in
the failure stage of the RIFLE classification [23] (see
details below in Study definitions), or at the onset of
criteria requiring emergency RRT. The study will be
conducted in 24 ICUs (15 university teaching hospitals
and 9 general (non-academic) hospitals) in France. All
patients admitted to the ICUs of participating centers
will be screened for eligibility. The study sponsor is the
University Hospital of Dijon, France, where data will be
managed by the Centre for Clinical Investigation and
Clinical Epidemiology (CIC-EC).
Inclusion criteria
 Age >18 years.
 Patients in the first 48 hr of septic shock developing
AKI with at least one criterion characteristic of the
failure stage of the RIFLE classification (defined
below under Study definitions).
 Informed consent provided by the patient (or person
with decisional responsibility).
 Patients must have social security cover.
Exclusion criteria
The following conditions will lead to ineligibility for study
entry:
 Chronic RRT.
 Obstructive etiology for AKI.
 Need for emergency RRT before randomization
(hyperkalemia >6.5 mmol/L, metabolic acidosis with
pH < 7.15 or extravascular fluid overload refractory
to diuretics with pulmonary edema).
 AKI that has already been treated by RRT in the ICU. Confirmed or suspected pregnancy (verified by
serum [b-HCG] pregnancy test if necessary).
 Patient is moribund with expected death within 24 hr.
 Patients for whom survival to 28 days is unlikely due
to an uncontrollable comorbidity (cardiac, pulmonary
or hepatic end-stage disease; hepatorenal syndrome;
poorly controlled cancer; severe post-anoxic
encephalopathy; etc.).
 Patients with advance directives issued expressing
the desire not to be resuscitated.
 Patient under tutorship, curatorship or judicial
protection.
 Enrollment in any concomitant randomized trial
with mortality as a primary outcome.
Study definitions
Septic shock
Septic shock is defined according to current guidelines
[24,25] as sepsis-induced hypotension persisting despite
adequate fluid replacement, requiring the initiation of
vasopressor therapy. The initial phase of septic shock is
defined as the first 48 hr after the start of vasopressor
therapy.
Sepsis
The operational definition of the clinical syndrome of
sepsis will be confirmed or suspected infection, and at
least two systemic inflammatory response syndrome
criteria, i.e. any two of the following: temperature >38°C
or <36°C; heart rate >90 beats/min; respiratory rate >20
breaths/min, PaCO2 < 32 mmHg or mechanically venti-
lated; white cell count >12,000 cells/mm3, <4,000 cells/
mm3 or with >10% immature (band) forms.
Acute renal failure
AKI will be defined and classified according to the RIFLE
criteria (risk of renal dysfunction, injury to the kidney,
failure of kidney function, loss of kidney function and
end-stage kidney disease) as outlined by the Acute Dialysis
Quality Initiative (ADQI) Working Group [23]. In brief,
the RIFLE criteria classify AKI into three categories of
severity (risk, injury and failure) and two categories of
clinical outcome (loss and end-stage kidney disease)
based on relative changes to serum creatinine and urine
output. The presence of AKI will be defined by the failure
stage of the RIFLE classification, namely an abrupt (within
7 days) reduction in kidney function, characterized by a
threefold increase in serum creatinine relative to baseline;
an absolute value ≥354 μmol/L (accompanied by an acute
increase ≥44.2 μmol/L); a reduction in urine output
of ≤0.3 mL/kg/hr for ≥24 hr; or anuria for ≥12 hr. If pre-
hospital baseline serum creatinine is unavailable, baseline
serum creatinine is estimated based on back-calculation
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(MDRD) as recommended by the ADQI [23].
Treatment
Renal replacement therapy
RRT will include any form of extracorporeal RRT for
patients with documented AKI. Given the lack of demon-
strated superiority of continuous over intermittent tech-
niques, and of convective over diffusive techniques [26,27],
investigators at each center will be free to choose the
extra-renal purification technique based on their usual
practice (intermittent hemodialysis, intermittent sustained
low-efficiency dialysis (SLED), continuous hemodialysis,
continuous hemofiltration or continuous hemodiafil-
tration) and can move from one technique to another
depending on the needs of the patient (typically the
continuous technique in the acute phase, followed by
intermittent techniques after stabilization).
Vascular access is obtained through a double lumen
catheter with a minimum diameter of 12 French, prefer-
ably implanted in the superior vena cava via the jugular
approach, and whose end is positioned 1 cm from the
junction between the superior vena cava and the right
atrium, or alternatively at the inferior vena cava by the
femoral route. Catheter placement under ultrasound
guidance is strongly recommended but not mandatory.
Investigators must follow international guidelines on the
management of AKI [28,29] to standardize practices and
optimize metabolic control and hemodynamic stability
during treatment.
For continuous techniques, investigators must provide
treatment continuously for 24 hr with a change of mem-
branes at least every 72 hr. To be certain of administer-
ing the recommended dialysis dose despite interruptions
for changing filters or for additional procedures away
from the ICU, investigators must regulate a minimum
ultrafiltration (or dialysate) rate of 25 mL/kg/hr.
For intermittent techniques, the recommendations are
to set a blood flow rate of 150 to 250 mL/min, a dialys-
ate flow rate of 300 to 500 mL/min, a high concentration
of sodium in the dialysate (150 mmol/L) and a low
temperature of the dialysate (35°C). Treatment should
be initiated with an isovolemic connection (simultaneous
connection of two lines filled with saline). The length
of sessions must be at least 4 hr and preferably 6 hr or
more. The frequency of sessions should be at least
once every 48 hr, or more often if investigators deem
it necessary to achieve optimal metabolic control, a
urea concentration <30 mmol/L or a stable salt and
water balance. Investigators will be required to use
biocompatible membranes.
Investigators can use systemic anticoagulation with
unfractionated heparin or low molecular weight heparin,
or alternatively, regional citrate anticoagulation.Early renal replacement therapy
The operational definition of early RRT is the initiation
of RRT immediately after the diagnosis of AKI. A max-
imum of 12 hr is allowed between the diagnosis of AKI
and the actual initiation of RRT, given the time required
for dialysis catheter placement and installation of equip-
ment for RRT, and allowing for technical difficulties that
may be encountered in clinical practice.
Delayed renal replacement therapy
The operational definition of delayed RRT is the initiation
of RRT at least 48 hr after the diagnosis of AKI. A max-
imum margin of 12 hr (i.e. up to 60 hr) is allowed before
actual initiation of RRT, justified by the same technical
reasons mentioned above for the early RRT group.
Emergency renal replacement therapy
By protocol and to minimize the potential bias of clinician
discretion on when to initiate emergency RRT, at least one
of the following criteria must be fulfilled prior to initiation
of emergency RRT:
1) hyperkalemia ([K+] ≥6.5 mmol/L) with characteristic
electrocardiographic changes
2) metabolic acidosis (pH <7.15) defined as a base
deficit > 5 mEq/L or HCO3
– < 18 mEq/L
3) pulmonary edema
Renal recovery
Renal recovery is defined as the return of spontaneous
urine output ≥1,000 mL/24 hr (or ≥2,000 mL/24 hr with
diuretics) for a minimum of 24 hr without RRT.
Trial protocol
Description of study flow
Patients will be identified in the ICU through daily sur-
veillance by the research coordinator or treating ICU
physician. Each patient’s eligibility will be verified by use
of a checklist that summarizes the inclusion and exclusion
criteria (Figure 1). Septic shock is considered as confirmed
once vasopressor therapy is initiated. For patients diag-
nosed with septic shock, AKI must appear within 48 hr for
the patient to be eligible (in addition to the failure criteria).
Sample size calculation
It has been shown that the mortality of septic shock
patients who develop AKI is around 50%. Assuming an
absolute reduction in mortality of 10% (55% mortality
at 90 days in the delayed RRT group versus 45% in the
early RRT group), 864 patients (432 per group) are required
to ensure 80% power at a bilateral alpha risk of 0.05,
assuming a rate of 5% non-evaluable cases.
The expected reduction of 10% in mortality was chosen
as a clinically relevant difference by the study team. There
Figure 1 Flow chart of the study groups. The timing of diagnosis, randomization and initiation of renal replacement therapy in the early and
delayed groups, according to the method used to diagnosis acute kidney injury, are shown.
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precedent for this, due to wide variations between existing
studies in the types of patients included, the definitions of
AKI used, and the definition of what constitutes early or
late treatment. In light of the heterogeneous data available,
a conservative estimate of a 10% reduction was retained as
being clinically relevant.
Informed consent
When patients meet the inclusion criteria, and do not
present any non-inclusion criteria, they are informed
(orally, with supporting documentation in written for-
mat) about the study by the investigators, and invited to
participate. If the patient is temporarily incapable of
receiving the appropriate information or making an
informed decision regarding consent to participate, they
can still be included if informed consent is given by the
patient’s surrogate or legal representative. If the patient
subsequently regains the capacity to understand the
study procedures and provide informed consent, their
consent must be obtained. Patients can be included in
emergency situations if their condition precludes consentand no legal representative or close relative is available to
provide consent. In this case, the investigator notes and
justifies in the patient’s medical record that the patient
was temporarily unable to receive the study information
and provide informed consent, and that no legal represen-
tative or close relative could be reached. Written consent
must subsequently be obtained from the patient, as soon
as their clinical status allows.
Randomization
Randomization is performed during the first 48 hr of septic
shock after the development of at least one criterion
defining the failure grade of the RIFLE classification.
Randomization takes place after verification of the eligi-
bility criteria, following an online request by the investi-
gator using Tenalea® software (Formsvision BV, Abcoude,
Netherlands). This allocation is based on a minimization
technique taking into account the center, age, sequential
organ failure assessment (SOFA) score, site and type of
infection. Patients are randomly assigned to one of the
two groups in a 1:1 ratio. Due to the nature of the study
intervention, blinding is not possible. However, the CIC-
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reports for the Data Safety and Monitoring Board. The in-
vestigators at the participating sites will remain unaware
of study group outcomes until the database is locked.
Study intervention
Initiation of RRT
Patients randomized to the early RRT arm will immediately
undergo dialysis catheter placement. A maximum of 12 hr
is allowed between the diagnosis of AKI and the actual
initiation of RRT; this allows for the time required for
catheter placement and installation of the RRT equipment,
as well as any technical difficulties that may be encountered
in clinical practice.
Patients randomized to the delayed RRT group will
be closely monitored for 48 hr after randomization to
identify as soon as possible the appearance of criteria
requiring emergency RRT as defined above. If any of
these criteria occur, dialysis catheters are placed and
the RRT will be initiated as soon as possible.
In the absence of the appearance of criteria requiring
emergency RRT, patients randomized to the delayed RRT
group will undergo insertion of the dialysis catheter and
initiation of RRT at least 48 hr after the diagnosis of
AKI, with a maximum margin of 12 hr allowed (i.e. up to
60 hr maximum), justified by the same technical reasons
mentioned above for the early RRT group.
If a patient in the delayed RRT group recovers normal
renal function (defined according to the criteria for
recovery of renal function listed above) within the 48 hr
after randomization, the investigator is free to choose
the most suitable treatment and is therefore not obliged to
dialyze the patient, but must, in this case, document the
absence of RRT and the normalization of renal function.
Data collection
Detailed clinical procedure-related RRT parameters, and
physiologic and laboratory data will be collected. Blood
and urine will be collected at baseline, 12, 24, 36 and 48 hr
and once daily thereafter until the study participants
are discharged from ICU. Data will be collected on
standardized case report forms (CRFs). All adverse events
will be recorded on the CRF on specific pages reserved
for this purpose. A simplified procedure will be used
for foreseeable adverse events (hemodynamic instability,
rhythm disturbances, electrolyte or acid-base imbalance,
and bleeding events related to hemodialysis catheters
or anticoagulants). Adverse events will be considered as
serious if they cause death, are life-threatening, cause
hospitalization (or prolongation of initial hospitalization),
cause disability or cause permanent damage, a congenital
anomaly or birth defect. Investigators must report any
serious adverse event to the sponsor (the University
Hospital of Dijon, France) promptly by email or telephone,followed by a written report within 48 hr. Completed
CRFs will be returned to the CIC-EC and entered into a
secured central database for independent quality control
and centralized analysis.
Clinical data obtained will include demographic charac-
teristics, comorbidities and prescribed and current drug
therapy. Details of admission diagnoses, surgical status,
and dates of hospital and ICU admission will be recorded.
Detailed data on AKI and on septic shock will be recorded
on the date of enrollment: interventions (i.e. mechanical
ventilation, vasoactive drugs and fluid therapy), hemo-
dynamics (i.e. blood pressure, heart rate and central
venous pressure), nephrotoxic drugs (e.g. aminoglycosides,
radiocontrast agents and hydroxy-ethyl starch), details of
sepsis (i.e. site of infection and effectiveness of anti-
microbial therapy) and acute physiology (i.e. components
of severity of illness and SOFA score, simplified acute
physiology score (SAPS II), urine output, fluid balance
and secondary non-kidney organ dysfunction). During the
trial, data will be collected on daily urine output, fluid
balance, electrolytes, acid-base status, serum creatinine
and urea, and components of the SOFA score. Data will
be collected each day on whether the primary endpoint
(mortality) has occurred, for evidence of any secondary
endpoints and for criteria for trial discontinuation. Finally,
any study protocol violations will be recorded.
All enrolled patients will be followed to determine
mortality, continued need for RRT or renal recovery
until death or discharge from hospital (whichever occurs
first) and at 28, 90, 180 days and 1 year after randomization.
Health-related quality of life will be assessed using the
EQ-5D form by telephone contact at 90 days and 1 year.
The EQ-5D is a generic health-related quality of life
measurement instrument comprising five multiple choice
questions, and a 100-point overall health state visual
analogue scale (VAS) [30]. The questions concern mobil-
ity, self-care, daily activities, pain, anxiety and depression.
The respondent is required to select one of three ordinal
answers best describing their health state in relation to
these five domains. Scores are then converted to an overall
utility score, with 0 representing death, and 1 representing
perfect health.Statistical analysis
All enrolled patients will be included in the main popu-
lation analysis. The primary analysis will be by intention
to treat (ITT). The characteristics of the two groups will
be compared using the usual univariate tests (chi-squared
or Fisher’s exact test for categorical variables, and ana-
lysis of variance or Mann–Whitney test for quantitative
variables, as appropriate). The main comparison of the
proportion of deaths at 90 days in both treatment groups
will be performed using Fisher’s exact test, with secondary
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the log rank test, and Cox regression.
For the per-protocol analysis, patients will be grouped
according to the time of initiation of the RRT. If RRT is
initiated within 12 hr after the onset of the failure stage
according to the RIFLE classification, then the patient
will be included in the early RRT group. Conversely, if
RRT is initiated >12 hr beyond this period, the patient will
be included in the delayed RRT group. The per-protocol
analysis will use the same techniques as the ITT analysis.
If the ITT and/or per-protocol analyses show a benefit
of early (<12 hr) initiation of RRT, a secondary analysis
will be performed using an extension of the proportional
hazards model proposed by Abrahamowicz and MacKenzie
[31] to estimate the non-proportional and non-log-linear
effects, taking into account the exact time since initiation of
RRT. This model will make it possible to trace the effect
of initiation of RRT over time, thus visualizing whether
early initiation results in lower risk of death after adjusting
for major confounders, taking into account any non-
proportional and/or non-log-linear effects. The main
conclusion of the test will only cover the ITT analysis.
Two interim analyses will be performed after the inclusion
of, respectively, 200 and 400 patients.
Safety will be analyzed by assessing the frequency of
arterial hypotension requiring the introduction or increase
of noradrenaline, pulmonary edema due to overload,
cardiac arrhythmias (ventricular tachycardia, ventricular
fibrillation, torsade de pointes and atrio-ventricular block
grade III), severe metabolic disorders and blood transfu-
sions (≥3 units of packed red blood cells) in both groups
and comparing rates using the appropriate tests, with an
alpha risk set at 0.05.
The frequency of death within 90 days after random-
ization will be recorded in both groups and compared
using a chi-squared test with alpha risk set at 0.0001 for
both interim analyses, according to the method proposed
by Peto [32] so as not to change the level of significance
of the final primary analysis.
All analyses will be performed under the guidance of
the Data Safety Monitoring Board, who will decide on
the necessity to recommend premature interruption of
the study to the Steering Committee, according to the
results of the interim analyses.
Secondary analyses
1. An analysis identical to the primary analysis, studying
mortality at 28 days taking an alpha risk of 0.05.
2. Average length of ICU stay and in-hospital stay will
be described and compared for survivors.
3. The number of days without mechanical ventilation
and the number of days without RRT in the two
groups will be compared. Deceased patients areconsidered as having a number of days without
mechanical ventilation and without RRT equal to
zero. The numbers of days will be compared in both
groups using a Mann–Whitney test.
4. Dependence on dialysis at hospital discharge will be
compared between groups using the chi-squared or
Fisher’s exact test. If the groups appear imbalanced
in terms of the pre-existence of non-dialyzed chronic
renal failure or administration of nephrotoxic drugs,
then logistic regression will be performed to adjust for
these factors.
5. The frequency of occurrence of at least one episode
of hypotension requiring the introduction or
increase of noradrenaline, pulmonary edema due to
overload, cardiac arrhythmias (ventricular
tachycardia, ventricular fibrillation, torsade de
pointes and atrio-ventricular block grade III), severe
metabolic disorders and blood transfusions (≥3 units
of packed red blood cells) will be compared between
groups using the chi-squared or Fisher’s exact test.
6. The number and characteristics of patients in the
delayed RRT group for whom the occurrence of a
criterion for emergency RRT was observed will be
described.
These comparisons will be performed by ITT and
per protocol. All analyses will be performed using SAS
Version 9.2 (SAS Institute Inc, Cary, NC, USA) by the
team of statisticians at the CIC-EC of the University
Hospital of Dijon, France. The significance level is set
at 0.05 for all final analyses.
Data safety and monitoring
The trial has an independent data safety and monitoring
committee with four members: two medical doctors
(one intensive care specialist and one nephrologist), one
statistician and one pharmacologist. These people are in-
dependent of the principal investigator and have no fi-
nancial, scientific or other conflict of interest with the
trial. Current or past collaborators of the principal inves-
tigator are not eligible to serve on the committee. Mem-
bers of the committee have expertise in intensive care
(acute kidney injury, septic shock and RRT), clinical trial
methodology and biostatistics.
Ethical considerations
This study was evaluated and received authorization
from the Ethics Committee (Comité de Protection des
Personnes (CPP) Est I) under the reference number
2012-A00519-34 and from the French National Health
Products Safety Agency (Agence National de Sécurité
des Médicaments et des Produits de Santé, ANSM).
Data processing methods are reported to the national
authority for the protection of privacy and personal data
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Specific insurance for the study has been arranged with the
Hospital Mutual Insurance Company, policy no 129234.
Discussion
This protocol for a randomized controlled study investi-
gating the impact of the timing of RRT initiation should
provide an answer to a key question in the management
of patients with AKI in the context of septic shock, for
whom the mortality rate remains close to 60% despite
improved understanding of the pathophysiology and recent
therapeutic advances. For the last ten years, the key
message in the treatment of septic shock has been the
optimization of initial management. Taking a closer
look at this concept, it seems legitimate to hypothesize
that early treatment of AKI during septic shock could
improve prognosis for patients.
It might have been preferable to initiate RRT at an
even earlier stage of AKI; however, at the injury stage of
the RIFLE classification, only 12% of patients have been
shown to need RRT in observational studies [33], and it
is not acceptable in ethical terms to initiate RRT so early.
To the best of our knowledge, no novel biomarker or
other parameter yet makes it possible to detect the need
for RRT at an earlier stage, and with sufficient accuracy.
For the delayed group, we chose a time delay of 48 hr
as we considered this to be sufficiently long to achieve
hemodynamic stability in septic shock, and to observe a
spontaneous improvement in renal function, in the best-
case scenario. In case of progression to AKI, it is not
ethically acceptable to delay RRT by any more than 48
hr. Lastly, we chose to use the term ‘delayed’ rather than
‘late’, because ‘late’ has previously been used to refer to
much longer time spans, such as beyond 5 days in one
study [19].
Clinical research on AKI has traditionally been difficult
due to the lack of standardized definitions. A recent
survey revealed the use of at least 35 definitions in the
literature [34]. To minimize this problem and to generalize
the results easily, we chose the RIFLE classification, which
is widely known and has been validated by large series
from Europe [35], the USA [36] and Australia [37],
each including several thousand patients. The Acute
Kidney Injury Network (AKIN) classification [38] did
not substantially modify the definition of the failure
stage (stage 3 in the AKIN classification) [39,40]. The
recent classification proposed by the Kidney Disease:
Improving Global Outcomes (KDIGO) guidelines had
not been published at the start of our study [29].
The presence of criteria for emergency dialysis could
be a barrier to good compliance in our study. To avoid
this problem, we decided to exclude from the study
patients who fulfilled emergency RRT criteria at ICU
admission before randomization, although this couldactually be a selection bias by limiting the inclusion of
the most seriously ill patients. On the other hand,
emergency criteria after randomization pose no problem
for the study, because RRT will be initiated immediately
regardless of the randomization group. The data will then
be analyzed by ITT but also per protocol.
Another situation that may arise is that patients in the
delayed RRT group recover adequate kidney function
before RRT is initiated, and are not on RRT at 48 hr, but
subsequently renal function gradually alters and RRT is
started later. These patients will still be included in the
ITT analysis and considered as adverse events, but a
subgroup analysis of these patients is planned, since they
constitute a particularly serious population with a very
high mortality and therefore, merit evaluation.
Potential challenges with the trial
If this study confirms the hypothesis that early RRT
treatment is superior in the specific condition of AKI in
septic shock patients, then this may help to reduce
mortality for this very serious disease. The absence of a
positive result will encourage us to focus our efforts on
other aspects of the early management of these patients
by delaying the initiation of renal supplementation.
Trial status
Recruitment is ongoing (200 patients included as of 16
June 2014).
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